Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page revision was bumped from v3.6.4 to v3.6.5, signaling a minor version update to the page. It does not change the substantive study details or visible information.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3, indicating a software version update for the site. This update does not change the displayed trial information or how users interact with the page.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3 on the page, indicating a software deployment update.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2 on the page. This minor version update does not change any study information or user-facing content.SummaryDifference0.1%

- Check64 days agoChange DetectedInvestigator attribution was split into a standalone name entry and new metadata lines (Last verified, Last known status). The page also introduces new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a standardized label for Intervention/Treatment.SummaryDifference2%

- Check72 days agoChange DetectedA new revision tag labeled Revision: v3.5.5 appears, replacing the prior Revision: v3.5.4.SummaryDifference0.1%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.